Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 2617 • 2014 ACR/ARHP Annual Meeting
No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study
Aikaterini I. Arida¹, Maria Konsta¹, Alexios Iliopoulos², Maria Tektonidou³, George Konstantonis¹, George D. Kitas⁴, Athanasios D. Protogerou¹ and Petros P. Sfikakis¹, ¹First Department of Propedeutic Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ²Department of Rheumatology, Veterans Administration Hospital, Athens, Greece, ³First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Background/Purpose: Chronic inflammatory arthritis is associated with increased cardiovascular disease (CVD) risk. The mechanisms behind this link include chronic inflammation, comorbidities and disease-related drugs. CV…
Abstract Number: 2553 • 2014 ACR/ARHP Annual Meeting
Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study
Nisha Nigil Haroon¹, Eva Szabo², Janet Raboud³, Ammepa Anton⁴, Robert Josse¹, Robert D. Inman¹ and Angela Cheung¹, ¹Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Osteoporosis Program, UHN, TOronto, ON, Canada, ³Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose Patients with ankylosing spondylitis (AS) have high fracture risk. BMD, bone microarchitecture and strength determine fracture risk. However, in AS, DXA-based BMD measurements of…
Abstract Number: 852 • 2014 ACR/ARHP Annual Meeting
Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Martin Rudwaleit², Désirée M. van der Heijde³, Walter P. Maksymowych⁴, Maxime Dougados⁵, Philip J. Mease⁶, Jürgen Braun⁷, Atul A. Deodhar⁸, Bengt Hoepken⁹, Tommi Nurminen⁹ and Robert B. M. Landewé¹⁰, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Endokrinologikum, Berlin, Germany, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶Division of Rheumatology Research, Swedish Medical Center and University of Washington, Seattle, WA, ⁷Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ⁸Oregon Health and Sciences University, Portland, OR, ⁹UCB Pharma, Monheim, Germany, ¹⁰Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Previous reports of RAPID-axSpA (NCT01087762) demonstrated efficacy and safety of certolizumab pegol (CZP) in patients (pts) with axial spondyloarthritis (axSpA) including pts with ankylosing…
Abstract Number: 587 • 2014 ACR/ARHP Annual Meeting
Clinical Characteristics of Nonradiographic Axial Spondyloarthritis in Korea: A Comparison with Ankylosing Spondylitis
Hyungjin Kim¹, Hyemin Jeong¹, Seulkee Lee¹, Inyoung Kim¹, Jiwon Hwang², Jaejoon Lee¹, Jinseok Kim³, Eun-Mi Koh⁴ and Hoon-Suk Cha⁵, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine,Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ³1753-3, Ara-1 Dong, Jeju National University Hospital, Jeju, South Korea, ⁴Dept of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: To evaluate the clinical characteristics and outcomes of nonradiographic axial spondyloarthritis (nr-axSpA) in Korean patients. Methods: A retrospective analysis evaluated 155 patients with nr-axSpA…
Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting
Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?
Proton Rahman¹, Algis Jovaisas², William Bensen³, Wojciech Olszynski⁴, Anna Jaroszynska⁵, Philip Baer⁶, Maqbool Sheriff⁷, Dalton Sholter⁸, Eliofotisti Psaradellis⁹, John S. Sampalis⁹, Francois Nantel¹⁰, Allen J Lehman¹¹, Susan Otawa¹¹ and May Shawi¹⁰, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Burlington, ON, Canada, ⁶Private Practice, Scarborough, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
Abstract Number: 2594 • 2014 ACR/ARHP Annual Meeting
Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment
Marketa Fojtikova¹, Karel Pavelka¹, Sarka Forejtova² and Jindra Gatterova³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Rheumatology, Institute of Rheumatology, Prague, Czech Republic, ³Institute of rheumatology, Prague 2, Czech Republic
Background/Purpose Inflammatory involvement of peripheral enthesis belongs to an important sign of spondyloarthritis (SpA). It may occur in patients with long-term as well as newly…
Abstract Number: 2512 • 2014 ACR/ARHP Annual Meeting
Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry
Vittorio Grosso¹, Roberto Gorla², Piercarlo Sarzi-Puttini³, Fabiola Atzeni⁴, Raffaele Pellerito⁵, Enrico Fusaro⁶, Giuseppe Paolazzi⁷, Pier Andrea Rocchetta⁸, Ennio Giulio Favalli⁹, Antonio Marchesoni¹⁰ and Roberto Caporali¹¹, ¹Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²Reumatologia, Spedali Civili, Brescia, Italy, ³Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁵Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁶Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁷Rheumatology, Santa Chiara Hospital, Trento, Italy, ⁸Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, ¹¹Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Golimumab therapy retention rates in patients with rheumatoid arthritis and seronegative spondyloarthritis: data from the Italian LORHEN registry Background/Purpose The efficacy of Golimumab (GLM) treatment…
Abstract Number: 819 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing
Dominique L. Baeten¹, Juergen Braun², Xenofon Baraliakos³, Joachim Sieper⁴, Maxime Dougados⁵, Paul Emery⁶, Atul A. Deodhar⁷, Brian Porter⁸, Ruvie Martin⁸, Shephard Mpofu⁹ and Hanno Richards¹⁰, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany, ⁵Université Paris René Descartes and Hôpital Cochin, Paris, France, ⁶University of Leeds, Leeds, United Kingdom, ⁷Oregon Health and Sciences University, Portland, OR, ⁸Novartis Pharma AG, East Hanover, NJ, ⁹Novartis Pharma AG, Basel, Switzerland, ¹⁰Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland
Background/Purpose A phase 2, proof-of-concept study indicated that secukinumab, an anti–IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk)…
Abstract Number: 583 • 2014 ACR/ARHP Annual Meeting
What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction
Proton Rahman¹, Michel Zummer², Wojciech Olszynski³, Majed Khraishi⁴, Dalton Sholter⁵, Rafat Faraawi⁶, William Bensen⁷, Milton Baker⁸, Andrew Chow⁹, Julie Vaillancourt¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J Lehman¹², Susan Otawa¹² and May Shawi¹¹, ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Université de Montréal, Montreal, QC, Canada, ³University of Saskatchewan, Saskatoon, SK, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁸University of Victoria, Victoria, BC, Canada, ⁹University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose Despite the importance of the Health Assessment Questionnaire (HAQ) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in assessing patient-reported functional status and disease…
Abstract Number: 246 • 2014 ACR/ARHP Annual Meeting
Neuropathic PAIN in Patients with Ankylosing Spondylitis
Pinar Borman¹, Ferda Kaygisiz², Aysegul Yaman¹ and Aynur Karagoz², ¹Department of Physical Medicine and Rehabilitation, University of Hacettepe Faculty of Medicine, Ankara, Turkey, ²Clinic of Physical Medicine and Rehabilitation, Ankara Training and Research Hospital, Ankara, Turkey
Background/Purpose: There is only one study in the literature indicating that neuropathic pain occurs in ankylosing spondylitis (AS) (1). Methods: The aim of this cross…
Abstract Number: 2613 • 2014 ACR/ARHP Annual Meeting
Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis
Walter P. Maksymowych¹, S Wichuk², Z Zhao³, P Chiowchanwisawakit⁴, RG Lambert⁵ and Sj Pedersen⁶, ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³PLA General Hospital, Beijing, China, ⁴Mahidol University, Bangkok, Thailand, ⁵Radiology, University of Alberta, Edmonton, AB, Canada, ⁶Dept. of Rheumatology, Copenhagen Center for Arthritis Research, Copenhagen, Denmark
Background/Purpose: Inflammation at vertebral corners on MRI has been shown to predict development of syndesmophytes in patients with AS. However, it is unclear at a…
Abstract Number: 2303 • 2014 ACR/ARHP Annual Meeting
Clinical Observation on Ankylosing Spondylitis Patients with Different Phenotypes
Zhiming Lin¹, Jun Qi², Jieruo Gu³ and Pingping Zhang⁴, ¹The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²The Third Affiliated Hospital of Sun Yat-sen University, guangzhou, China, ³Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ⁴Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background/Purpose :Juvenile and adult forms of ankylosing spondylitis (AS) have been shown different in initial symptoms,clinical presentation ,imaging manifestations and prognosis.So,according to the diagnostic criteria…
Abstract Number: 614 • 2014 ACR/ARHP Annual Meeting
The Association of PPM1A with Inflammasome Activation in Ankylosing Spondylitis
Soo Min Ahn¹, Seung-Hyeon Bae¹, Seokchan Hong¹, Eun-Ju Lee¹, Eun-Jin Lee², Eun-Ju Chang², Doo-Ho Lim¹, Yong-Gil Kim¹, Chang-Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
The Association of PPM1A with Inflammasome Activation in Ankylosing SpondylitisBackground/Purpose Ankylosing spondylitis (AS) is a chronic inflammatory disorder usually affecting axial skeleton and joints. The…
Abstract Number: 564 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis
Sylvain Mathieu¹ and Martin Soubrier², ¹Hopital Gabriel Montpied, Clermont Ferrand, France, ²Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France
Background/Purpose: Rheumatoid arthritis is associated with increased cardiovascular risk. In the guidelines, ankylosing spondylitis (AS) is considered to have an equally high cardiovascular risk. The…
Abstract Number: 42 • 2014 ACR/ARHP Annual Meeting
The Prevalence of Ankylosing Spondylitis in Sweden – a Nationwide Register Study
Sofia Exarchou¹, Ulf Lindström², Johan Askling³, Jonas Eriksson⁴, Helena Forsblad-d'Elia², Lars Erik Kristensen⁵, Martin Neovius⁴, Carl Turesson¹ and Lennart T. Jacobsson², ¹Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ³Clinical Epidemiology Unit, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden
Background/Purpose: Reported Ankylosing Spondylitis (AS) prevalence estimates vary considerably, and there is a lack of nationwide estimates. Previous studies by our group support the validity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].